



NEWS RELEASE

Novation and Université de Montréal/CRCHUM present at Target ALS Annual Meeting May 3-5, 2022

FOR IMMEDIATE RELEASE

July 4, 2022

Port Coquitlam, Canada: Novation Pharmaceuticals Inc. and their collaborators at the Université de Montréal/CRCHUM's, Dr. Christine Vande Velde and Dr. Alex Parker, reported on promising results at the Target ALS Annual Meeting in Boston, MA, May 3-5, 2022.

Dominique Cheneval, Novation CEO, described how the use of Novation's ALS Quest assay identified selective, small molecule up-regulators of G3BP1, a key player in the stress granule response, and their potential use for the treatment of ALS and FTD.

Drs. Vande Velde and Parker reported on exciting functional data for the selective compound hits. The Quest-identified compounds increased the motility of *C. elegans* in an ALS paralysis model and restored *G3BP1* mRNA levels to normal. Dr. Vande Velde's work has shown that altered regulation of the *G3BP1* transcript, via its translation and stability, plays a key role in neurodegenerative disorders, such as ALS and FTD.

About Novation and its *Quest* Technology

Novation is a product-focused company that identifies new therapeutics for a broad range of diseases, including neurodegeneration. The Company developed *Quest*, its breakthrough drug-discovery technology that harnesses the natural cellular control function of mRNA modulation. The technology uses cell-based assays to identify small molecules that impact protein expression via mRNA modulation.

The ability to affect mRNA function with small molecular weight compounds can impact a wide range of disease areas from therapeutic intervention, including "non-drugable" targets, to diseases currently treated with biologicals. As a non-biased approach, *Quest* can identify both inhibitory and stimulatory small molecule compounds that modulate the stability of a target mRNA or influence its translatability.

Novation's suite of *Quest* drug-discovery assays span a number of disease areas, with targets in oncology, inflammation, cardiometabolic dysfunction, neurodegeneration and dyslipidemia. Novation is also developing assays for COVID-19 and other areas where there is a great need for small molecule therapeutics.

This news release contains certain forward looking statements. Actual results may differ materially from the statements made as a result of various factors, including, but not limited to, the inherent risks associated with drug research and development, difficulties or delays in development testing, changes in regulatory affairs, lack of therapeutic efficacy, unacceptable side-effects, the dependence on partners, the inability to raise sufficient finance, the appearance of competitors and other risks generally associated with the biopharmaceutical industry.

For further information contact:

Dominique Cheneval, Ph.D.
CEO and Co-Founder
Novation Pharmaceuticals Inc.
104 - 2071 Kingsway Avenue
Port Coquitlam, B.C., Canada V3C 6N2
Telephone: 604.552.0768
Email: dcheneval@novation-pharma.com
Web site: www.novation-pharma.com